Geode Capital Management’s Spero Therapeutics SPRO Stock Holding History

Geode Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	566,329 +46,407	+9%	+$121K	﹤0.01%	3307
2026 Q1	$1.22M	Sell	519,922 -9,273	-2%	-$22K	﹤0.01%	3302
2025 Q4	$1.23M	Buy	529,195 +1,718	+0.3%	+$3.99K	﹤0.01%	3314
2025 Q3	$992K	Buy	527,477 +16,778	+3%	+$36.9K	﹤0.01%	3382
2025 Q2	$1.48M	Sell	510,699 -14,170	-3%	-$20.4K	﹤0.01%	3218
2025 Q1	$378K	Buy	524,869 +43,741	+9%	+$36.9K	﹤0.01%	3645
2024 Q4	$496K	Sell	481,128 -59	-0%	-$70	﹤0.01%	3603
2024 Q3	$645K	Sell	481,187 -11,000	-2%	-$14.8K	﹤0.01%	3513
2024 Q2	$640K	Buy	492,187 +22,746	+5%	+$34.3K	﹤0.01%	3480
2024 Q1	$808K	Buy	469,441 +56,734	+14%	+$88.9K	﹤0.01%	3442
2023 Q4	$607K	Hold	412,707	–	–	﹤0.01%	3542
2023 Q3	$500K	Buy	412,707 +21,902	+6%	+$30.3K	﹤0.01%	3605
2023 Q2	$567K	Buy	390,805 +52,949	+16%	+$90.6K	﹤0.01%	3593
2023 Q1	$490K	Buy	337,856 +80,572	+31%	+$135K	﹤0.01%	3653
2022 Q4	$445K	Sell	257,284 -32,974	-11%	-$61.6K	﹤0.01%	3711
2022 Q3	$580K	Hold	290,258	–	–	﹤0.01%	3645
2022 Q2	$215K	Sell	290,258 -180,931	-38%	-$526K	﹤0.01%	4212
2022 Q1	$4.1M	Buy	471,189 +14,005	+3%	+$143K	﹤0.01%	2914
2021 Q4	$7.32M	Buy	457,184 +12,270	+3%	+$195K	﹤0.01%	2657
2021 Q3	$8.19M	Buy	444,914 +31,153	+8%	+$500K	﹤0.01%	2606
2021 Q2	$5.78M	Buy	413,761 +50,150	+14%	+$701K	﹤0.01%	2814
2021 Q1	$5.35M	Buy	363,611 +5,463	+2%	+$96.1K	﹤0.01%	2757
2020 Q4	$6.94M	Buy	358,148 +158,719	+80%	+$2.47M	﹤0.01%	2403
2020 Q3	$2.23M	Buy	199,429 +2,729	+1%	+$32.3K	﹤0.01%	2822
2020 Q2	$2.66M	Buy	196,700 +41,476	+27%	+$466K	﹤0.01%	2687
2020 Q1	$1.25M	Buy	155,224 +35,772	+30%	+$315K	﹤0.01%	2918
2019 Q4	$1.15M	Buy	119,452 +2,670	+2%	+$28.8K	﹤0.01%	3231
2019 Q3	$1.24M	Buy	116,782 +2,065	+2%	+$21.8K	﹤0.01%	3154
2019 Q2	$1.32M	Buy	114,717 +20,376	+22%	+$245K	﹤0.01%	3141
2019 Q1	$1.21M	Buy	94,341 +2,499	+3%	+$26.5K	﹤0.01%	3083
2018 Q4	$564K	Buy	91,842 +3,876	+4%	+$31.4K	﹤0.01%	3326
2018 Q3	$924K	Buy	87,966 +34,476	+64%	+$400K	﹤0.01%	3251
2018 Q2	$784K	Buy	53,490 +33,094	+162%	+$423K	﹤0.01%	3278
2018 Q1	$290K	Buy	+20,396	New	+$247K	﹤0.01%	3579

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management's SPRO Position: Q2 2026 in Review

Geode Capital Management increased its Spero Therapeutics (SPRO) stake by 8.9% in Q2 2026, buying an estimated $121K and bringing the position to 566,329 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

Geode Capital Management first reported a position in SPRO in Q1 2018 and has held it in 34 quarters since. The position peaked at $8.19M in Q3 2021. 36 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Geode Capital Management held 566,329 shares of Spero Therapeutics worth $1.25M as of Q2 2026.
Geode Capital Management bought 46,407 Spero Therapeutics shares in Q2 2026, an estimated $121K.
Spero Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3307 holding.
Geode Capital Management first reported a position in Spero Therapeutics in Q1 2018 and has held it in 34 quarters since.
Geode Capital Management's Spero Therapeutics position peaked at $8.19M in Q3 2021.
36 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.